Effects of impaired renal function on the pharmacokinetics and toxicity of i.v. ZD9331, a novel non-polyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors

Anti-Cancer Drugs

Volumn 13, Issue 6, 2002, Pages 645-653

  De Jonge, Maja J A ^a   Glimelius, B ^a   Verweij, Jaap ^a   Van Groeningen, C ^a   Bonneterre, J ^a   De Vries, E G E ^a   Culine, S ^a   Young, J ^a   Smith, Rob ^a   Droz, J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Pharmacology; Renal dysfunction; Thymidylate synthase inhibition

Indexed keywords

PLEVITREXED; THYMIDYLATE SYNTHASE INHIBITOR; ANTINEOPLASTIC AGENT; CREATININE; ENZYME INHIBITOR; QUINAZOLINE DERIVATIVE; THYMIDYLATE SYNTHASE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CREATININE CLEARANCE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG POTENCY; FEMALE; HUMAN; KIDNEY CLEARANCE; KIDNEY FAILURE; LIQUID CHROMATOGRAPHY; LIVER CLEARANCE; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; SOLID TUMOR; TANDEM MASS SPECTROMETRY; BLOOD; BLOOD CELL COUNT; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; HEMATOLOGIC DISEASE; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DISEASE; METABOLISM; MIDDLE AGED; NEOPLASM;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BLOOD CELL COUNT; CREATININE; ENZYME INHIBITORS; FEMALE; HEMATOLOGIC DISEASES; HUMAN; INJECTIONS, INTRAVENOUS; KIDNEY DISEASES; MALE; MIDDLE AGE; NEOPLASMS; QUINAZOLINES; SUPPORT, NON-U.S. GOV'T; THYMIDYLATE SYNTHASE; HUMANS; MIDDLE AGED;

EID: 0036021029     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200207000-00012     Document Type: Article

References (25)

1. The catalytic mechanism and structure of thymidylate synthase
2. Folate-based thymidylate synthase inhibitors as anticancer agents
3. Thymidylate synthase inhibitors
4. Antifolates in clinical development
5. Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines
6. The antitumour activity of ZD9331, a non-polyglutamatable quinazoline thymidylate synthase inhibitor
7. The influence of drug-exposure conditions on the development of resistance to methotrexate or ZD1694 in cultured human leukemia cells
8. Molecular characterization of human acute leukemia cell line resistant to ZD9331, a non-polyglutamatable thymidylate synthase inhibitor
9. Molecular characterisation of two cell lines selected for resistance to the fate-based thymidylate synthase inhibitor, ZD1694
10. New folate analogues of the 10-deaza-aminopterin series. Basis for structural design and biochemical and pharmacologic properties
11. Obligate genetic expression in tumor cells of a fetal membrane property mediating 'folate' transport: Biological significance and implications for improved therapy of human cancer
12. Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: A water-soluble, non-polyglutamatable, quinazoline-based inhibitor of thymidylate synthase
13. ZD9331, a novel non-polyglutamated thymidylate synthase inhibitor: In vivo antitumour efficacy and toxicity to normal murine tissues
14. A phase I pharmacokinetic study of ZD9331, a novel long-acting thymidylate synthase inhibitor on a single dosing every 3 weeks schedule
15. Phase I study of ZD9331 on short daily intravenous bolus infusion × 5 days every 3 weeks with fixed dosing recommendations
16. Phase I trial of ZD9331 in adult patients with refractory solid malignancies administered by 30-min infusion on days 1 and 8 with the cycle repeated every 3 weeks
17. Phase I trial of ZD9331, a non-polyglutamatable thymidylate synthase (TS) inhibitor given as a 5-day continuous infusion
18. ZD9331 as second- or third-line therapy in patients with advanced colorectal cancer: A phase II multicenter trial
19. Phase II trial of ZD9331 as third-line therapy for patients with ovarian carcinoma
20. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function
21. Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264
22. Changes in the clearance of total and unbound etoposide in patients with liver dysfunction
23. Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565
24. Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites
25. 14C]-ZD9331 infused over 30 minutes in patients with advanced solid tumors